AstraZeneca Focuses On COVID-19 Antibody Approach After Year Of Vaccine Headwinds
Jab Sales Strong Despite Hurdles
During its fourth quarter earnings call, the UK-based major expressed hopes that its prophylactic antibody approach would fare better after its COVID-19 jab faced several obstacles in developed markets last year.
You may also be interested in...
AstraZeneca Buys Into COVID-19 Antibodies From Newly Launched RQ Bio
The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.
AZ's COVID-19 Antibody Combo Protects For Longer But Access Issues Persist
AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.
AstraZeneca’s Pangalos: Cultural Diversity Is Key To Educating Scientists
Mene Pangalos talked to Scrip about the importance of cultural diversity in a lab setting, pushing the frontiers on public-private partnerships and redoubling efforts on gene editing.